NH PHL Discipline A Microbiology Analytical Track 5 capability-capacity development

NH PHL 学科 A 微生物学分析 Track 5 能力-能力发展

• 批准号: 10173074
• 负责人: Christine Louise Bean
• 金额: $ 7.5万
• 依托单位: NH STATE DEPT/HLTH STATISTICS/DATA MGMT
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10173074
• 关键词: NH; PHL; Discipline; Microbiology; Analytical

Discipline A: Microbiology Analytical Track 5: Microbiology Capability/Capacity Development To build additional capability and expand the national capacity in microbiological areas of emerging technology where the FDA has identified a specific need. The NH PHL will develop the capability to test for Cyclospora in human food product and environmental samples. The New Hampshire Public Health Laboratories (NH PHL) will purchase appropriate equipment and supplies such as filters, rotary shaker, vacuum manifold, heating block and reagents. The NH PHL has thermocyclers, Dynal bead system, fluorescent microscope and gel electrophoresis systems. Personnel will be trained on the FDA BAM 19b method: Molecular Detection of Cyclospora cayetanensis in Fresh Produce using real-time PCR. Appropriate proficiency testing will be either purchased or developed in-house to demonstrate competency in the newly developed method. NH PHL will participate and pass annual proficiency tests, attend the LFFM Face-to-Face meeting and monthly calls, maintain ISO 17025 accreditation, maintain facilities and personnel necessary to complete the work proposed, and provide a detailed quarterly summary of all samples collected and analyzed. The NH PHL will maintain a valid 20.88 agreement with the FDA.

学科A：微生物学 分析轨道5：微生物学能力/能力发展 建设更多的能力并扩大国家在微生物领域的能力 FDA已确定特定需求的新兴技术。NH PHL将开发 检测人类食品和环境样本中的环孢子菌的能力。 新汉普郡公共卫生实验室(NH PHL)将购买适当的设备 以及过滤器、旋转振动器、真空歧管、加热块和试剂等用品。《NH》杂志 PHL拥有热循环仪、动态微珠系统、荧光显微镜和凝胶电泳 系统。人员将接受FDA BAM 19b方法的培训：分子检测 生鲜农产品中卡氏环孢子虫的实时定量聚合酶链式反应。适当的能力测试 将购买或在内部开发，以展示在新的 改进的方法。 NH PHL将参加并通过年度水平测试，参加LFFM面对面会议 每月来电，维护ISO17025认证，维护必要的设施和人员 完成拟议的工作，并提供收集到的所有样本的详细季度总结 并进行了分析。NH PHL将与FDA保持20.88年的有效协议。